Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015238 | 0.70 | KMT2A (0.34) | PTGDR2KMT2A | |
| SCHEMBL10715229 | 0.61 | PTGDR2 (0.56) | PTGDR2KMT2A | |
| SCHEMBL4015237 | 0.60 | PTGDR2 (0.36) | PTGDR2KMT2A | |
| SCHEMBL30688439 | 0.59 | MAOA (0.50) | PTGDR2 | |
| SCHEMBL22436349 | 0.59 | MAOA (0.50) | PTGDR2 | |
| SCHEMBL16542312 | 0.59 | HRH3 (0.32) | KMT2A | |
| Hydroquinone SCHEMBL8070696 | 0.59 | CA2 (0.52) | KMT2A | |
| Benzene SCHEMBL27638324 | 0.59 | ALOX15 (0.48) | KMT2A | |
| SCHEMBL11556832 | 0.58 | ALOX15 (0.50) | PTGDR2KMT2A | |
| SCHEMBL231282 | 0.58 | TSHR (0.61) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009085040-A1 | PROTEIN KINASE INHIBITORS | DCB-USA LLC (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | BRAF, MAP3K20, SELENOI | PTGDR2 2110/4885KMT2A 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.